DIJON, France--(BUSINESS WIRE)--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the ...
In 2024, OPM focused on its priority assets and programs: OPM-101 and COMETE (development of radioligands with its partner Navigo Proteins). Our rigorous cost management enabled us to reduce operating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results